Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone are used as g...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy 2016-10, Vol.18 (1), p.214-214, Article 214
Hauptverfasser:	Miner, Jeffrey N, Tan, Philip K, Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T, Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Format:	Artikel
Sprache:	eng
Schlagworte:	Care and treatment Cell Line Clinical trials Dosage and administration Gout Health aspects Humans Kidney - drug effects Male Organic Anion Transporters - drug effects Organic Cation Transport Proteins - drug effects Probenecid Thioglycolates - pharmacokinetics Triazoles - pharmacokinetics Uric acid Uric Acid - blood Uricosuric Agents - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!